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1. Introduction
  Brucel los is  and tuberculosis  are  two chronic 
granulomatous infectious diseases that are ubiquitous in 
the developing world. Brucellosis is now considered to be 
the commonest zoonosis in the world with a global annual 
incidence of more than a half million[1], and is specifically 
endemic to developing countries[2-3]. It is produced by 
infection with any of several members of the Brucella 
family including Brucella melitensis, Brucella abortus and 
Brucella suis. Human brucellosis results from ingestion 
or inhalation of the organism, or inoculation through skin 
abrasions. Once in the bloodstream, the organism replicates 
within the reticuloendothelial system. Being facultatively 
intracellular, the organism can survive and multiply within 
phagocytic cells, evading immune-mediated clearance[1]. 
Persistent infection and resultant activation of the 
immune system, results in a state of chronic inflammation, 
characterized by hypergammaglobulinemia and elevated 
erythrocyte sedimentation rate. Clinical correlates of 
reticuloendothelial activity include hepato-splenomegaly 
and lymphadenopathy. Histopathology of affected tissues 
including lymph nodes and bone marrow frequently 
reveals non-caseating granulomas[4]. These laboratory and 
histologic features of chronic brucellosis share similarity 
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with tuberculosis-another infectious disease endemic to 
many developing countries. 
  This study was therefore designed to identify characteristic 
clinical, laboratory and histopathologic features of 
tuberculosis in patients with culture proven brucellosis, 
in order to assess the likelihood of misdiagnosis as 
tuberculosis.
2. Materials and methods
2.1. Study settings
  Kasturba Medical College, Manipal is a major tertiary 
care hospital in Southwestern India. It has a catchment 
area corresponding to the district of Udupi in which it is 
situated, and the neighbouring districts of Uttara Kannada 
and Dakshina Kannada, with a combined population 
approximately 4.36 million individuals.
  A retrospective analysis was performed on patients 
diagnosed with culture proven brucellosis between January 
and December 2011, based on review of their medical 
records. Patients with demonstrable co-infection with 
tuberculosis in the form of positive identification of acid 
fast bacilli in sputum or tissue samples and/or isolation 
of Mycobacteria tuberculosis in culture from any sample, 
were excluded. Clinical features, laboratory parameters 
and tissue histopathology reports where available were 
noted. Specifically, features suggestive of tuberculosis were 
looked for. Among clinical features, a history of prolonged 
fever (>4 weeks), chronic productive cough, significant 
weight loss (>10% of baseline body weight prior to onset of 
illness), evening rise of temperature, and night sweats were 
noted. Risk factors for tuberculosis including a history of 
exposure to a known case of tuberculosis, and any form 
of immunosuppression including HIV infection, chronic 
kidney disease, and diabetes mellitus were identified. Risk 
factors for brucellosis such as occupational exposure were 
noted. Clinical stigmata of tuberculosis including respiratory 
disease, lymphadenopathy, and hepato-splenomegaly 
were recorded. Laboratory markers of tubercular disease 
including elevated ESR, hypergammaglobulinemia, and 
tissue evidence of granulomatous disease were also looked 
for.
2.2. Statistical analysis
  All data was analysed using SPSS Statistics version 17.0 




  Thirty-two patients with brucellosis were included in 
the study. Mean age at presentation was (34.28暲13.52) 
years. Twenty-four of the patients were male, yielding a 
male:female ratio of  3:1. 
  Chronic fever was (>4 weeks) seen in 21 (65.63%) patients, 
evening rise of temperature in 11 cases (34.38%), while 13 
(40.63%) had a productive cough. Significant weight loss was 
seen in 8 cases (25%), night sweat in 5 cases (15.63%). Other 
symptoms suggestive of tubercular disease were also noted. 
Of the 32 patients, nine (28.13%) reported at least three of 
these symptoms. Two patients had four symptoms, while one 
patient had all five symptoms. Six patients denied any of 
these symptoms. Careful search for risk factors showed that 
three (9.38%) patients had known risk factors for tuberculosis, 
while six (18.75%) had risk factors for brucellosis. The 
majority of patients denied risk factors for both tuberculosis 
and brucellosis.
  Clinical examination revealed significant lymphadenopathy 
in seven (21.88%) patients. Hepatomegaly and splenomegaly 
were observed in fifteen (46.88%) and twelve (37.50%) 
patients respectively. Eight (25.00%) patients had hepato-
splenomegaly, of these only two had associated significant 
lymphadenopathy. Interestingly respiratory examination was 
normal in all patients, including those complaining of cough. 
Review of laboratory parameters showed an ESR greater 
than 50 mm/hr in eight (25.00%) patients; of these 
patients, it was greater than 100 mm/hr in five (15.63%). 
Hypergammaglobulinemia was seen in eight (25.00%) cases. 
Bone marrow biopsy showed non-caseating granulomas in 
three (9.38%) cases, lymph node biopsy showed granulomas 
in one case. Chest radiograms were normal in all patients.
All patients received standard chemotherapy with oral 
doxycycline and rifampicin. Twelve patients also received 
initial therapy with parenteral streptomycin.
4. Discussion
  Diagnosis of brucellosis requires isolation in culture of the 
organism from blood[5] and/or bone marrow[6], or serologic 
evidence of infection by the standard tube agglutination[7] 
or enzyme linked immunosorbent assay[8]. Needless to 
say, these diagnostic techniques are often unavailable in 
many areas of developing countries, resulting in significant 
underreporting of cases[9]. It is quite reasonable to surmise 
that a proportion of these patients might be misdiagnosed 
as tuberculosis based on similarities in presentation and 
basic laboratory parameters. Fortunately, several anti-
tubercular drugs including rifampicin and streptomycin 
also possess excellent activity against Brucella species[10]. 
However, the opposite case is equally plausible wherein 
a patient diagnosed with brucellosis may have underlying 
tuberculosis. Treatment with standard therapy in such 
cases entails exposure of the patient to inadequate doses 
and duration of anti-tubercular drugs, likely increasing the 
chance of development of drug-resistant tuberculosis.
  Drug resistance in tuberculosis is rapidly becoming a 
global problem, and now threatens to overcome progress 
achieved in tuberculosis control. Estimated global annual 
incidence of multidrug resistant (MDR) tuberculosis is 
approximately 440 000[11]. Of these cases, nearly half are 
present in India and China[11]. The direct economic fallout 
of MDR tuberculosis is a rise in healthcare costs-resulting 
from drug sensitivity testing, and prolonged therapy with 
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expensive second-line drugs[12].
  The principal driving force behind the emergence of these 
MDR strains is now known to selective antibiotic pressure[13] 
by inadequate or inappropriate drug therapy, promoting 
survival of mutant organisms that are resistant to first-line 
therapy[14,15]. In such a situation, the importance of rational 
use of anti-tubercular drugs cannot be over-emphasized. 
While several studies have demonstrated the clinical overlap 
between tuberculosis and other infectious diseases such as 
melioidosis[16] and histoplasmosis[17-19], it is pertinent to note 
that treatment for these conditions is entirely different, in 
sharp contrast to brucellosis. Chemotherapy for brucellosis 
includes rifampicin and streptomycin-two first-line 
antitubercular drugs, prescribed over a period of six weeks. 
The WHO oral regimen consists of 200 mg doxycycline and 
600 mg rifampicin daily for at least 6 weeks[10]; the alternate 
oral/parenteral regimen replaces rifampicin with 15 mg/kg
parenteral streptomycin daily for the first 14-21 days of 
treatment[20,21]. Uncontrolled prescription of these drugs 
without conclusively ruling out underlying tuberculosis can 
be disastrous for the patient. Given the large geographical 
overlap and high prevalence of both these diseases, 
such a scenario is certainly feasible and is a potentially 
unrecognized contributor to the development of MDR 
tuberculosis. Our study demonstrates the remarkable degree 
of overlap between chronic brucellosis and tuberculosis, 
both in terms of clinical presentation and basic laboratory 
parameters. The relatively low proportion of patients with 
risk factors emphasizes the unreliability of these factors in 
making a diagnostic decision.
  In summary, beyond the obvious diagnostic dilemmas that 
such mimicry can pose, there are also major implications 
for treatment in the similarity between brucellosis and 
tuberculosis. Physicians should exercise extreme care 
in ruling out co-existent tuberculosis before initiating 
therapy in all patients with proven brucellosis. Empirical 
antibiotic therapy for suspected brucellosis is best avoided 
altogether. Risk factors for brucellosis and tuberculosis are 
poor indicators and should not be relied upon to make the 
distinction, especially in developing countries with high 
prevalence of both diseases.
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